Timothy Voorhees

Has grant

Assistant Professor - Clinical

The Ohio State University Wexner Medical Center

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Timothy Voorhees is an Assistant Professor in the Clinical department at The Ohio State University Wexner Medical Center in the United States. His research areas include the clinical outcomes of various lymphomas, particularly marginal zone lymphoma and classic Hodgkin lymphoma, as well as the application of CAR-T cell therapy. He has contributed to significant studies examining the impact of age on lymphoma biology and the prognostic relevance of circulating lymphoma cells. His work aims to enhance treatment strategies and patient outcomes in hematologic disorders.

Recent Grants

Grant: Close

Phase Ib Study to Assess the Safety and Efficacy of Epcoritamab in Relapsed and Refractory PTLD

Open Date: 2023-04-01

Close Date: 2025-10-31

Articles (18)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (18)

Peter Riedell

University of Chicago

UNITED STATES

Timothy Voorhees

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (18)

Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centers.

Siltuximab for chimeric antigen receptor T-cell therapy-related CRS and ICANS: a multicenter retrospective analysis.

Impact of Age on Biology, Presentation and Outcomes in Marginal Zone Lymphoma: Results From a Multicenter Cohort Study

SOHO State of the Art Updates and Next Questions Updates on Building Your CAR-T Cell Program

Prognostic relevance of circulating lymphoma cells at diagnosis in newly diagnosed follicular lymphoma patients

Post-infusion PD-1+CD8+CAR-T cells identify patients responsive to CD19-CAR-T therapy in non-Hodgkin's lymphoma

Outcomes associated with allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma in the era of novel agents

Successful obinutuzumab administration after rituximab discontinuation due to intolerance in patients with hematologic disorders

Treatment of primary mediastinal B-cell lymphoma with dose-adjusted REPOCH during pregnancy

Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: Outcomes from 15 U.S. institutions.

A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma

Impact of circulating lymphoma cells at diagnosis on outcomes in patients with Waldenstrom macroglobulinemia.

Real-world evidence of the safety and survival with CD19 CAR-T cell therapy for relapsed/refractory solid organ transplant-related PTLD.

A multi-center analysis of the impact of DA-EPOCH-R dose-adjustment on clinical outcomes of patients with double/triple-hit lymphoma.

Identifying aggressive subsets within diffuse large B-cell lymphoma: implications for treatment approach

An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma.

Assessment of Salvage Regimens Post-Chimeric Antigen Receptor T Cell Therapy for Patients with Diffuse Large B Cell Lymphoma.

Pretherapy metabolic tumor volume is associated with response to CD30 CAR T cells in Hodgkin lymphoma

Collaborators (18)

Peter Riedell

Reem Karmali

James Godfrey

John Reneau

Jorge Florindez

Abdullah Khan

Lapo Alinari

XIAOLI ZHANG

Miriam Jacobs

chunhua song

Narendranath Epperla

Yazeed Sawalha

Marcus Geer

David Bond

Monalisa Ghosh

Michael Slade

Ajay Major

Saarang Deshpande

Make your next move.